KSQ’s recent publication offers computationally derived HRD scores for over 1300 cancer cell lines
KSQ Therapeutics shared a post on LinkedIn about a recent paper by Anne Dodson et al. published in Cancer Research Communications:
“Homologous Recombination Deficiency (HRD) plays a crucial role in the development and progression of several cancers. KSQ’s recent publication in Cancer Research Communications offers computationally derived HRD scores for over 1300 cancer cell lines.
This resource will help enhance the understanding of HRD, its potential as a predictive biomarker for DNA repair targeting agents, and how HRD may be exploited to discover new therapies. Kudos to the KSQ Data Science Team for leveraging their precision and expertise to create this valuable resource!”
“Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines”
Authors: Anne Dodson, Sol Shenker, Pamela Sullivan, Sumeet Nayak, Chris Middleton, Michael McGuire, Edmond Chipumuro, Yuji Mishina, Erica Tobin, Louise Cadzow, Andrew Wylie, Dipen Sangurdekar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023